An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.

Husseini, Jad S; Amorim, Bárbara Juarez; Torrado-Carvajal, Angel; Prabhu, Vinay; Groshar, David; Umutlu, Lale; Herrmann, Ken; Cañamaque, Lina García; Garzón, José Ramón García; Palmer, William E; Heidari, Pedram; Shih, Tiffany Ting-Fang; Sosna, Jacob; Matushita, Cristina; Cerci, Juliano; Queiroz, Marcelo; Muglia, Valdair Francisco; Nogueira-Barbosa, Marcello H; Borra, Ronald J H; Kwee, Thomas C; Glaudemans, Andor W J M; Evangelista, Laura; Salvatore, Marco; Cuocolo, Alberto; Soricelli, Andrea; Herold, Christian; Laghi, Andrea; Mayerhoefer, Marius; Mahmood, Umar; Catana, Ciprian; Daldrup-Link, Heike E; Rosen, Bruce; Catalano, Onofrio A

MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use.

European journal of nuclear medicine and molecular imaging, 2021, Vol 48, Issue 5, p1522

1619-7089

Journal Article

10.1007/s00259-021-05198-2